Skip to content
TrialScanner

NCT05986851

Azeliragon in MGMT Unmethylated Glioblastoma

Phase 2Active, not recruitingMEDPCollaborator

Registry record

Lead sponsor
Cantex Pharmaceuticals
Conditions
Glioblastoma
Primary completion
Sep 30, 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT05986851 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05986851: Azeliragon in MGMT Unmethylat... | TrialScanner